Mass photometry enables rapid, purification-free quantification of rAAV vectors, offering a faster solution for gene therapy manufacturing.

Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), ...

Collectively, the data from in vitro and in vivo studies using FUS, TDP-43, and C9orf72 models demonstrate that hUPF1 holds significant potential for treating the majority of patients with ALS and ...

The AAV9-CaMKIIα0.4 vector eliminated viral shedding in 90% of treated eyes and reduced TG HSV-1 DNA by 51%. The presentations can be accessed on the Excision website at ...

The event brought together thought leaders advancing health-system pharmacy in the management, delivery, and optimization of advanced therapeutics.

Melbourne’s Peter MacCallum Cancer Centre – aka Peter Mac – is Australia’s only public hospital dedicated to cancer care, ...

RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026 Pivotal trial more than half enrolled, with completion expected in 2025 Additional ...

Mitochondrial DNA (mtDNA) editing has emerged as a revolutionary approach in the fight against neurodegenerative diseases (NDDs).